4.5 Article

A 5-year look-back at the notification and management of vaccine supply shortages in Germany

期刊

EUROSURVEILLANCE
卷 27, 期 17, 页码 -

出版社

EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2022.27.17.2100167

关键词

-

资金

  1. German Ministry of Health [COVID-19]

向作者/读者索取更多资源

This study provides a retrospective analysis of supply issues and measures in Germany in the context of European and global vaccine supply constraints. The study found that vaccine supply shortages in Germany were mainly caused by increased demand, changes in vaccine recommendations, and global immunisation program changes. Shortages of a shorter duration could be mitigated using existing storage capacities, while longer shortages often required the use of alternative products and redistribution.
Background: Unavailability of vaccines endangers the overall goal to protect individuals and whole populations against infections. Methods: The German notification system includes the publication of vaccine supply shortages reported by marketing authorisation holders (MAH), information on the availability of alternative vaccine products, guidance for physicians providing vaccinations and an unavailability reporting tool to monitor regional distribution issues. Aim: This study provides a retrospective analysis of supply issues and measures in the context of European and global vaccine supply constraints. Results: between October 2015 and December 2020, the 250 notifications concerned all types of vaccines (54 products). Most shortages were caused by increased demand associated with immigration in Germany in 2015 and 2016, new or extended vaccine recommendations, increased awareness, or changes in global immunisation programmes. Shortages of a duration up to 30 days were mitigated using existing storage capacities. Longer shortages, triggered by high demand on a national level, were mitigated using alternative products and re-allocation; in a few cases, vaccines were imported. However, for long lasting supply shortages associated with increased global demand, often occurring in combination with manufacturing issues, few compensatory mechanisms were available. Nevertheless, only few critical incidents were identified: (i) shortage of hexavalent vaccines endangering neonatal immunisation programmes in 2015;(ii) distribution issues with influenza vaccines in 2018; and (iii) unmet demand for pneumococcal and influenza vaccines during the coronavirus disease (COVID)-19 pandemic. Conclusion: Vaccine product shortages in Germany resemble those present in neighbouring EU states and often reflect increased global demand not matched by manufacturing capacities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据